Role of DLBS3233 in the Treatment of Subjects With New Onset of Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2014
At a glance
- Drugs DLBS 3233 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Dexa Medica
- 10 Jun 2017 Biomarkers information updated
- 07 Oct 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 07 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.